A Participant and Investigator-blinded, Randomized, Placebo-controlled Phase 2a Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of TIN816 in Patients With Sepsis-associated Acute Kidney Injury
Latest Information Update: 09 May 2025
At a glance
- Drugs TIN 816 (Primary)
- Indications Acute kidney injury
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 18 Apr 2024 This trial has been completed in Germany according to European Clinical Trials Database record.
- 03 Apr 2024 Planned End Date changed from 5 Mar 2024 to 23 Apr 2024.
- 03 Apr 2024 Planned primary completion date changed from 5 Mar 2024 to 23 Apr 2024.